{
    "clinical_study": {
        "@rank": "23555", 
        "acronym": "GOGER-01", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: 3 courses", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15."
            }, 
            {
                "arm_group_label": "Arm B: 6 courses", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to define whether 6 courses of neoadjuvant chemotherapy can\n      lead to a higher rate of complete cytoreductive surgery compared with 3 courses of\n      neoadjuvant chemotherapy in patients with epithelial ovarian cancer, fallopian tube cancer\n      or primary peritoneal cancer."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Cancer", 
            "Fallopian Tube Carcinoma", 
            "Peritoneal Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients \u226518 years.\n\n          -  Karnofsky Performance Scale \u2265 60%\n\n          -  Histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma or\n             primary peritoneal carcinoma with the exception of mucinous, clear cell and\n             carcinosarcoma histologies.\n\n          -  Documented International Federation of Gynecologic Oncology (FIGO) stage IIIC-IV\n             unsuitable for complete primary cytoreductive surgery. Inoperability must be\n             confirmed by open laparoscopy or by laparotomy.\n\n          -  Adequate bone marrow, liver and renal function to receive chemotherapy and\n             subsequently to undergo surgery:\n\n               -  white blood cells >3,000/\u00b5L, absolute neutrophil count \u22651,500/\u00b5L, platelets\n                  \u2265100,000/\u00b5L, hemoglobin \u22659 g/dL,\n\n               -  serum creatinine <1.25 x upper normal limit (UNL) or creatinine clearance \u226560\n                  mL/min according to Cockroft-Gault formula or to local lab measurement\n\n               -  serum bilirubin <1.25 x UNL, AST(SGOT) and ALT(SGPT) <2.5 x UNL.\n\n          -  Signed informed consent obtained prior to any study-specific procedures\n\n        Exclusion Criteria:\n\n          -  Mucinous, clear cell and carcinosarcoma histologies.\n\n          -  Synchronous or previous other malignancies within 3 years prior to starting study\n             treatment, with the exception of adequately treated non-melanomatous skin cancer or\n             carcinoma in situ (of the cervix or breast or other sites).\n\n          -  Patients with brain metastases, seizure not controlled with standard medical therapy,\n             or history of cerebrovascular accident (CVA, stroke) or transient ischemic attack\n             (TIA) or subarachnoid hemorrhage within 6 months from the enrollment on this study.\n\n          -  Any other concurrent medical conditions contraindicating surgery or chemotherapy that\n             could compromise the adherence to the protocol (including but not limited to impaired\n             cardiac function or clinically significant cardiac diseases, active or uncontrolled\n             infections, HIV-positive patients on antiretroviral therapy, uncontrolled diabetes,\n             cirrhosis, chronic active or persistent hepatitis, impaired respiratory function\n             requiring oxygen-dependence,serious psychiatric disorders).\n\n          -  Pregnant or breastfeeding women."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125513", 
            "org_study_id": "GOGER-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A: 3 courses", 
                "Arm B: 6 courses"
            ], 
            "intervention_name": "carboplatin and paclitaxel followed by surgery", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "neoadjuvant chemotherapy", 
            "ovarian cancer", 
            "fallopian tube carcinoma", 
            "peritoneal carcinoma", 
            "randomized study"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "claudio.zamagni@aosp.bo.it", 
                    "last_name": "Claudio Zamagni, MD", 
                    "phone": "+390516364548"
                }, 
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40138"
                    }, 
                    "name": "S.Orsola-Malpighi Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Claudio Zamagni, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pierandrea De Iaco, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martino Abrate, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Reggio Emilia", 
                        "country": "Italy"
                    }, 
                    "name": "IRCCS Ospedale Santa Maria Nuova"
                }, 
                "investigator": {
                    "last_name": "Martino Abrate, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma", 
        "overall_official": {
            "affiliation": "Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi", 
            "last_name": "Claudio Zamagni, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Agenzia Italiana del Farmaco (AIFA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant chemotherapy in patients with bulky stage IIIC or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer", 
            "measure": "Percentage of patients who obtain a complete cytoreduction (no macroscopic residual tumor) at surgery , as a comparative outcome measure of 3 vs 6 courses of neoadjuvant chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "within 6 weeks after the last cycle of chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125513"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi", 
            "investigator_full_name": "Claudio Zamagni MD", 
            "investigator_title": "MD Medical Oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To determine whether a longer duration of neoadjuvant chemotherapy is associated with a lower rate of perioperative grade 3-5 toxicities. The surgical adverse events are defined as:\nintraoperative, which occur during surgical procedure\nperioperative , which occur from day 1 to day 7 after surgery\npostoperative, which occur from day 8 to 30 days after surgery\nAdverse events list for surgical procedures:\nPostoperative death (<30 days); Hemorrhage/bleeding intraoperative or postoperative requiring at least transfusion of 2 units of non-autologous red blood cells; Vascular events: thrombosis/embolism, disabling or life-threatening vessel injury-artery or vein, symptomatic or life-threatening visceral arterial ischemia; Infections requiring IV antibiotics, antifungal or antiviral interventions or at risk for life-threatening consequences; Gastrointestinal fistula; Urinary fistula; Lymphocele, requiring medical or operative intervention.", 
            "measure": "Percentage of patients with grade 3-5 perioperative toxicity (according to CTCAE), as a measure of safety", 
            "safety_issue": "Yes", 
            "time_frame": "within 30 days after surgery"
        }, 
        "source": "Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}